[go: up one dir, main page]

EA200100636A1 - Усовершенствования порошков или связанные с порошками - Google Patents

Усовершенствования порошков или связанные с порошками

Info

Publication number
EA200100636A1
EA200100636A1 EA200100636A EA200100636A EA200100636A1 EA 200100636 A1 EA200100636 A1 EA 200100636A1 EA 200100636 A EA200100636 A EA 200100636A EA 200100636 A EA200100636 A EA 200100636A EA 200100636 A1 EA200100636 A1 EA 200100636A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
powder
powders
acid particles
microns
Prior art date
Application number
EA200100636A
Other languages
English (en)
Other versions
EA004045B1 (ru
Inventor
Дэвид Гандертон
Дэвид Александер Водден Мортон
Пол Лукас
Original Assignee
Вектура Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вектура Лимитед filed Critical Вектура Лимитед
Publication of EA200100636A1 publication Critical patent/EA200100636A1/ru
Publication of EA004045B1 publication Critical patent/EA004045B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glanulating (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

Частицы аминокислоты, такой как лейцин, могут быть получены из паров аминокислоты, например, с помощью аэрозольной конденсации или с помощью распылительной сушки. Частицы аминокислоты имеют объемную плотность не более чем 0,1 г/см, или имеют усредненный по массам медианный аэродинамический диаметр, не превышающий 10 мкм, или находятся в виде хлопьев, имеющих толщину, не превышающую 100 мкм. Включение частиц аминокислоты в порошок для использования в порошковых ингаляторах, как обнаружено, улучшает вдыхаемую долю активного материала в порошке.Отчет о международном поиске был опубликован 2000.10.12.
EA200100636A 1998-12-09 1999-12-09 Усовершенствования порошков или связанные с порошками EA004045B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827145.5A GB9827145D0 (en) 1998-12-09 1998-12-09 Improvements in or relating to powders
PCT/GB1999/004156 WO2000033811A2 (en) 1998-12-09 1999-12-09 Improvements in or relating to powders

Publications (2)

Publication Number Publication Date
EA200100636A1 true EA200100636A1 (ru) 2001-12-24
EA004045B1 EA004045B1 (ru) 2003-12-25

Family

ID=10843948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100636A EA004045B1 (ru) 1998-12-09 1999-12-09 Усовершенствования порошков или связанные с порошками

Country Status (24)

Country Link
US (1) US6989155B1 (ru)
EP (1) EP1137399B1 (ru)
JP (1) JP4410942B2 (ru)
KR (1) KR20010101138A (ru)
CN (1) CN1334723A (ru)
AT (1) ATE240093T1 (ru)
AU (1) AU770461B2 (ru)
BR (1) BR9916102A (ru)
CA (1) CA2353448C (ru)
CZ (1) CZ20012043A3 (ru)
DE (1) DE69907951T2 (ru)
DK (1) DK1137399T3 (ru)
EA (1) EA004045B1 (ru)
ES (1) ES2198973T3 (ru)
GB (1) GB9827145D0 (ru)
HU (1) HUP0104513A3 (ru)
MX (1) MXPA01005584A (ru)
NO (1) NO20012825D0 (ru)
NZ (1) NZ511965A (ru)
PL (1) PL348831A1 (ru)
PT (1) PT1137399E (ru)
SK (1) SK284775B6 (ru)
TR (1) TR200101591T2 (ru)
WO (1) WO2000033811A2 (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
CA2413692C (en) * 2000-06-27 2011-10-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
KR100949539B1 (ko) 2000-06-27 2010-03-25 벡투라 리미티드 약학 조성물용 입자의 제조 방법
EP1337239B2 (en) * 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP1337240B2 (en) † 2000-11-30 2014-09-24 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT1455755E (pt) 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2478801A1 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Method for administration of growth hormone via pulmonary delivery
ES2718455T3 (es) * 2002-03-20 2019-07-02 Civitas Therapeutics Inc Formulaciones terapéuticas sostenidas inhalables
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP1917301B1 (en) * 2005-08-05 2014-04-23 3M Innovative Properties Company Compositions exhibiting improved flowability
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CA2709772A1 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3153292A1 (en) 2008-06-13 2009-12-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US9877967B2 (en) 2010-01-26 2018-01-30 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2464346A1 (en) * 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
EP3536368B1 (en) * 2010-11-09 2025-09-17 MannKind Corporation Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
AU2015249177B2 (en) * 2010-11-09 2017-08-03 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
RU2448717C1 (ru) * 2011-04-20 2012-04-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Способ получения антикоагулянтно-фибринолитического средства на основе гепарина
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
LT2739268T (lt) 2011-08-01 2019-03-25 Monash University Inhaliacijos būdas ir kompozicija
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
KR20190036520A (ko) 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019118370A1 (en) * 2017-12-12 2019-06-20 Xotramorphic, Llc Compositions, methods, and systems for producing flocculent materials for special effects
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110441198A (zh) * 2018-05-03 2019-11-12 人福普克药业（武汉）有限公司 一种检测尼达尼布软胶囊中尼达尼布粒径的方法
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
US20230105108A1 (en) 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
IL149085A0 (en) * 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide

Also Published As

Publication number Publication date
CA2353448C (en) 2010-02-23
HUP0104513A2 (hu) 2002-03-28
EA004045B1 (ru) 2003-12-25
CN1334723A (zh) 2002-02-06
DK1137399T3 (da) 2003-08-18
WO2000033811A3 (en) 2000-10-12
US6989155B1 (en) 2006-01-24
EP1137399B1 (en) 2003-05-14
CZ20012043A3 (cs) 2001-12-12
NO20012825L (no) 2001-06-08
HUP0104513A3 (en) 2003-12-29
DE69907951T2 (de) 2004-03-11
MXPA01005584A (es) 2003-07-14
GB9827145D0 (en) 1999-02-03
ES2198973T3 (es) 2004-02-01
NO20012825D0 (no) 2001-06-08
AU770461B2 (en) 2004-02-19
PT1137399E (pt) 2003-09-30
CA2353448A1 (en) 2000-06-15
JP4410942B2 (ja) 2010-02-10
AU1577700A (en) 2000-06-26
TR200101591T2 (tr) 2001-11-21
EP1137399A2 (en) 2001-10-04
ATE240093T1 (de) 2003-05-15
WO2000033811A2 (en) 2000-06-15
BR9916102A (pt) 2001-09-04
SK284775B6 (sk) 2005-11-03
DE69907951D1 (de) 2003-06-18
SK7772001A3 (en) 2001-12-03
NZ511965A (en) 2003-09-26
KR20010101138A (ko) 2001-11-14
JP2002531487A (ja) 2002-09-24
PL348831A1 (en) 2002-06-17

Similar Documents

Publication Publication Date Title
EA200100636A1 (ru) Усовершенствования порошков или связанные с порошками
CA2432175A1 (en) Storage stable powder compositions of interleukin-4 receptor
GB9807232D0 (en) Aerosol composition
WO2007016435A3 (en) Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
TR199700722T1 (xx) Kuru toz p�sk�rt�c�lerde kullan�lmak i�in ta��y�c� par�ac�klar
CA2263445A1 (en) Pharmaceutical aerosol composition
CA2347856A1 (en) Dry powder for inhalation
IE872453L (en) A new system for administration of liposomes to mammals
CA2183577A1 (en) Methods and compositions for pulmonary delivery of insulin
LV12231A (lv) Dispersa makromolekulu kompozicija
MY114125A (en) Compositions for inhalation
PL343342A1 (en) Particulate active agent support for pulmonary application
WO2001051026A3 (en) Instant granules and process for their formulation
SE9701278L (sv) Pulverformigt biogent, av förbenade hjort framställt preparat och på det biogena preparatet baserad livsmedelstillsats
WO2005025535A8 (en) Methods for preparing pharmaceutical compositions
AU6611898A (en) Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
RU2008130171A (ru) Маскирование вкуса порошков
MXPA03003785A (es) Suspension de una proteina epi-hne, proceso de preparacion de la misma, aerosol en polvo seco derivado de la misma, composiciones farmaceuticas conteniendo dicha suspension o aerosol y sus usos.
FR2226434A1 (en) Free-flowing fine polymer coating powders for thin films - esp for electrostatic spraying, by pptg from sprayed polymer solns
CA2413692A1 (en) Method of making particles for use in a pharmaceutical composition
KR970704447A (ko) 푸시드산 정제의 제조방법(Preparation of fusidic acid tablets)
AR007807A1 (es) Polvo de aspartame para la aplicacion en mezclas de polvos y procedimiento para su preparacion
TH34685A (th) วัสดุสำหรับการผลิตวัสดุก่อสร้างหรือสิ่งของที่ถูกขึ้นรูปแล้ว

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU